In conclusion, we showed Sglt2 expression in medaka kidney and found that the highly specific SGLT2I, Tofo, prevents NASH progression by preventing steatosis and fibrosis. Here, SLC5A2 is linked to metabolic dysfunction-associated steatohepatitis.